Serum Interleukin-6 Level: A Potential Prognostic Indicator of Liver Damage Progression in Patients with Hepatitis B and C Virus Infection

Abstract

Background/Aims: Hepatitis B virus (HBV) and hepatitis C virus (HCV) immunopathogenesis depends significantly on cytokines. This investigation sought to determine the link between the cytokine interleukin-6 (IL-6) and the advancement of chronic infections, cirrhosis, and/or hepatocellular cancer (HCC) in individuals with HBV and HCV. Methods: In our study, we detected 35 patients with HBV and 35 patients with HCV and 18 healthy control persons in the period from December 2021 to June 2022. and detection of Serum IL-6 levels for HBV and HCV patients during the technique of enzyme-linked immunosorbent assay (ELISA). Results: Involve the samples 35 patients infected with HBsAg concentration (mean ±SE: 2.081 ± 0.0) aged (≥ 67) years old and 35 patients with HCV (mean ±SE: 1.394 ± 0.1562) aged (26-35) years old with more prevalence than other groups. The concentration of IL-6 level was statistically significantly higher in patients with HBV infection (mean ±SE: 15.56 ± 3.198) compare with HCV patients (mean ±SE: 31.20 ± 6.009) and control group (mean ± SE:1.389 ± 0.2508). and found a significant difference between HCV and the control group. Conclusions: The study reported elevated HBV infection in the elder group and highest in young patients with HCV infection that more exposure to infection and increased level of IL-6 in HBV and HCV patients. male more than female patients in both HBV and HCV.